ORKA (Oruka Therapeutics) Days Payable : 0.00 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Days Payable?

Oruka Therapeutics's average Accounts Payable for the six months ended in Dec. 2024 was $3.46 Mil. Oruka Therapeutics's Cost of Goods Sold for the six months ended in Dec. 2024 was $0.00 Mil.

The historical rank and industry rank for Oruka Therapeutics's Days Payable or its related term are showing as below:

ORKA's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 123.485
* Ranked among companies with meaningful Days Payable only.

Oruka Therapeutics's Days Payable stayed the same from . 20 (0.00) to Dec. 2024 (0.00).

Oruka Therapeutics Days Payable Historical Data

The historical data trend for Oruka Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Days Payable Chart

Oruka Therapeutics Annual Data

Trend

Dec24

Days Payable

Oruka Therapeutics Semi-Annual Data
	Dec24
Days Payable	-

Competitive Comparison of Oruka Therapeutics's Days Payable

For the Biotechnology subindustry, Oruka Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oruka Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oruka Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Oruka Therapeutics's Days Payable falls into.

Save Embed

;

Save Embed

;

Oruka Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Oruka Therapeutics's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: . 20 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (	+	3.462)	/	1 )	/	0	*	365
=	3.462					/	0	*	365
=	N/A

Oruka Therapeutics's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: . 20 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (	+	3.462)	/	1 )	/	0	*	365 / 2
=	3.462					/	0	*	365 / 2
=	N/A

Oruka Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Oruka Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

HQ1:Germany

Address

855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025

Website

https://www.orukatx.com

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.